Method of prevention of postoperative osteomyelitis |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method of prevention of postoperative osteomyelitis (RU 2343925):
 Amorphous alendronate monosodium, methods of production, based pharmaceutical composition and method of inhibition of bone resobrtion / 2334751
Invention refers to method of production of amorphous alendronate monosodium and to solid pharmaceutical composition having property to invoke bone bulk expansion and containing therapeutically effective amount of amorphous alendronate monosodium, produced by stated method. Method of production of amorphous alendronate monosodium includes solvent removal from alendronate monosodium solution using spray drying.
 Pharmaceutical formulation applied for prevention and treatment of bone tissue resorption of any etiology, transdermal delivery and treatment technique / 2325165
Given invention refers to pharmaceutical field, specifically to pharmaceutical formulation of gel dosage form applied for prevention and treatment of osteoporosis including as an active component bisphosphonate incorporated in phospholipid vesicles generated from lipid and hydrophilic phases, including components in the following proportions, mass %: bisphosphonate 0.01-2.0; egg lecithin 1.0-6.0; pine essence 0.05-0.2; camphor oil 0.01-1.0; olive oil 0.01-5.0; vitamin E 0.01-0.15; vitamin D 0.01-0.2; vitamin F 0.2-0.4; carbopole 0.4-0.6; NaOH 0.42; glycerol 2.0-4.0; nipagine 0.3; nypazole 0.1; water and others. In addition invention refers to treatment of bone tissue resorption of any etiology and osteoporosis for patients suffering from gastrointestinal disturbance with this composition.
 Osteoprotegrin, its application for preparation of pharmaceutical composition (variants), production of food substance (variants) and fodder, food substance, fodder and pharmaceutical composition for prevention and treatment of disorders related to bone remodeling, and/or immune disorders / 2324705
This invention is related to biotechnology, to be more precise, to preparation of proteins out of milk, and may be used for prevention or treatment disorders related to metabolism in bones and immune function. Osteoprotegrin is prepared out of human or cow milk and has glycolysis profile that produces polypeptide with molecular mass of approximately 80, 130 and 200 kilodaltons. Prepared protein is used in structure of food substance and pharmaceutical composition for prevention or treatment of disorders related with bone remodeling, and/or immune disorders. Also prepared protein is added to make fodder.
 Method for treating and preventing the loss of bony tissue / 2319483
The present innovation deals with treating and preventing the loss of bony tissue and/or increased development of bony tissue. For this purpose it is necessary to apply 15-lipoxygenase inhibitors. These molecules could be introduced either individually or in combination with agents that inhibit the resorption of bony tissue or additional agents that regulate calcium resorption out of bony tissue or increase the accumulation of bony tissue. The innovation enables to widen the assortment of medicinal preparations for treating diseases associated with the loss of bony tissue, such as osteoporosis, osteoarthritis, Paget's disease and those of periodontium and, also, the fractures.
Osteoplastic composite material / 2307661
Material comprises deproteinized allobone granules as filler, the granules being at least 1 mm large, and hydrophylic dimethylacrylate as monomer. Bone cement, filler and monomer are taken in 1:1:0.5 proportion, respectively.
 Analogs of vitamin d / 2301794
Invention relates to novel triaromatic compounds, namely, analogs of vitamin D of the general formula (I):
 Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using / 2299741
Invention relates to drugs used in prophylaxis and treatment of the locomotor system, in particular, degenerative-dystrophic joint and backbone diseases. Invention proposes a pharmaceutical composition normalizing metabolism in osseous and cartilage tissues and comprising the effective amount of peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component, and pharmaceutically acceptable carrier. Invention proposes peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] possessing the biological activity manifesting as normalization of metabolism in osseous and cartilage tissues. Invention proposes a method for prophylaxis and treatment of locomotor system by normalization of metabolism in osseous and cartilage tissues involving administration in a patient of a pharmaceutical composition containing as an active component peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] in the dose 0.01-100 mcg/kg of the body mass for at least once per a day for time necessary for achievement of the therapeutic effect. Invention can be used as agent normalizing metabolism in osseous and cartilage tissues.
 Method for optimizing bone reparative regeneration / 2297217
Method involves preparing bioantioxidant Thiophan solution with alpha-tocopherol oil solution taken as base taken in Thiophan 5 mg and alpha-tocopherol 5 ml proportion. The bioantioxidant solution is introduced at a dose of 3 mg/kg of body weight into intramedullary canal of damaged bone through polyvinylchloride catheter once a day, daily during 4 days, then, every other day. Total treatment course is 10 injections long.
Composition for bone tissue treatment in damages of inflammation etiology / 2296575
Claimed composition contains nutrient medium, 10 % serum of cow embryo, human fibroblast diploid cells and gel filler in the next component ratio (in 1 ml): nutrient medium 0,01-0,9; 10 % serum of cow embryo 0,001-0,2; suspension of human fibroblast diploid cells 1x105- 5x109 cells; and balance: gel filler. As human fibroblast diploid cells composition contains human fibroblast diploid cell strain from embryo lung tissue for substitutive therapy or human fibroblast diploid cell strain from embryo skin-muscle tissue for substitutive therapy. As gel filler 5 % polyethylene oxide may be used.
Method for stimulating osteogenesis at fractures of tubular bones / 2295969
The innovation suggested deals with treating osseous-destructive diseases of motor system. Thus, in case of the fractures of tubular bones it is necessary to introduce 0.1-0.2%-angiogenin solution isolated due to ultrafiltration out of cow's milk once into the fracture site. The innovation provides improved efficiency of stimulation at excluding the risk for infecting, allergic reactions and, also, the chance fir translocation of tumor cells associated with the use of angiogenin of another origin.
 Multipolar magnetic diamagnetic nanoparticles injector in biological tissue / 2337727
Multipolar magnetic diamagnetic nanoparticles injector in biological tissue consists of multipolar magnet all poles of which are provided within one plane being loaded side of injector. Poles are not spaced.
Method of treatment with bee sting / 2335306
Invention is referred to medicine area, namely to apiotherapy and can be used for treatment of various diseases in neurology, ophthalmology and other branches of medicine. Essence: a skin area that should be sting, is preliminary moistened with infusion of dead bees on 40-60% alcohol aqueous solution in the ratio of 100 units of dead bees on 100 ml of alcohol aqueous solution. The way allows accelerating and enlarging reliability of procedure.
 Active delivery of medication in gastrointestinal tract / 2334506
Device for medication introduction includes capsule which is to be taken-in. Capsule contains medication placed therein, environment ally sensitive mechanism, for instance, coating capable of changing its state in response to position of capsule in gastrointestinal tract of individual, absorption mechanism, which is capable of moving medication directly through endoepithelial layer of gastrointestinal tract in response to change of state of environment sensitive mechanism, and self-expanding part.
Method for treating with bee stinging / 2318546
It is necessary to activate a bee before putting it onto a certain skin part due to wetting this skin part with distilled water at the content of dry bee poison ranged 0.8-1.2 mg/8 ml water. The innovation provides acceleration and higher reliability of the above-mentioned procedure despite a bee's state.
 Device for treating hollow organs / 2313372
Device can be used for treating hollow organs in gynecology and proctology. Device has cylindrical case with distal oval-shaped end. Channel for pumping working medium in is made in distal end. Channel is connected with unit for pumping of working medium in. Cylindrical case is placed into elastic envelope. One end of envelope is closed and the other one is connected fastened at its circular groove. Channel for pumping working in is connected by recesses with circular grooves made onto side surface of cylindrical case.
 Method for treating opioid and/or alcoholic addiction / 2310449
It is necessary to implant a system with naltrexone into a patient's body; moreover, the implanted system should be supplied with means of dosing and delivering naltrexone into epidural space and has got a dosing pump. Naltrexone should be introduced into epidural space at the quantity of 2.5-5 mg on conversion to dry matter at interval ranged 10-24 h during prolonged period of time up to 365 d. The suggested therapy provides necessary concentration of naltrexone in a patient's spinal liquid at the required level in the course of the whole period of therapy, decreases harmful impact of naltrexone upon a body and decreases its expenses. It, also, makes it impossible for a patient to stop this therapy independently.
 The decrease of tissue volume / 2308967
The present innovation should be applied in case of pulmonary diseases that require decreased volume of affected pulmonary tissue or its sealing in case of spontaneous pneumothorax. So, through a bronchoscope applied towards a target part it is necessary to introduce certain material along a catheter. The quantity of the origin of this material should be sufficient for stimulating the adhesion between one collapse-affected sector of a pulmonary target part and another, and fibrosis of a pulmonary target part or around a pulmonary target part in which this collapse took place. The present material based upon pharmaceutical compositions contains a polypeptide growth factor, a component of extracellular matrix, a vasoactive substance and a proapoptotic agent. Moreover, the compositions additionally include fibrinogen or fibrin monomer, or fibrinogen's activator. The innovation enables to achieve directed stimulation of the adhesion of a target part, fibrosis of a target part itself or around the sector in which collapse took place.
 Method and the device for carrying out liposuction / 2297849
Method involves saturating skin layer above liposuction area with ozone/NO-containing substance. Then, hydrotreated adipose tissue tunnel or near-surface dispersion and emulsification is carried out. Primarily circumscribed superficial remote pneumopulse liposuction area is treated with ozone/NO-containing gas mixture, after vacuum evacuation of dispersed and emulsified adipose tissue, suturing incisions and placing fixing flexible bandage impregnated, for example, with ozone/NO-containing solution is carried out in superposition relative to liposuction area. And then, ultrasonic low-frequency superficial contact treatment of liposuction area is carried out. The device has means for producing ozone/NO-containing gas mixtures, high pressure air compressor, reservoir containing ozonized drug solution and pneumatic hydraulic unit. Beside that, the device has pneumatic hydraulic dispersing cannulas and limiting control unit, and acoustic unit having advanced radiation-emitting end face means.
 Method and device for increasing applied substance absorption by skin / 2297252
Device has vibrating probe head, electrode matrix placed on it, electric pulses oscillator electrically connected to the electrode matrix, at least one conducting roller, chamber available between the vibrating probe head and at least one conducting roller, and vacuum pump connected to the chamber for creating vacuum in it for stimulating skin suction. The electrode matrix is set in a way that electric pulses act upon the skin concurrently with mechanical vibrations applied to skin by means of a vibrating probe head to stimulate substance absorption by skin. The second embodiment of the invention allows electrode matrix to be set in a way that electric pulses act upon the skin concurrently with vacuum creation in the chamber to increase substance absorption, when placed on skin, before applying vacuum to skin and before applying electric pulses to skin. The method involves smearing the substance over skin to make absorption by skin start, vibration of frequency being equal to 10-200 Hz, the vibration being produced by means of vibrating head plate of manual probe which is imposed on skin, applying a sequence of electric impulses packages of frequency equal to 50-15000 Hz and maximum voltage of 20-200 V applied to electrode matrix imposed on skin. The electrodes matrix is located on vibrating plate and vacuum is applied to skin when carrying out previous operations for supporting uniform substance absorption with skin. Sequence of electric pulse packages and vibration treatment are concurrently applied to skin for intensifying skin substance absorption. Method for reducing cellulitis involves applying mechanical vibrations to skin by means of vibrating probe head, applying electric pulses to skin by means of probe head, simultaneously with mechanical vibrations concurrently applied to skin due to previous operations. Suction in skin is stimulated with the probe head in the probe direction, when it moves over skin.
 Method and device for introducing eye implants / 2294722
Device has elongated body, cannula, pusher and binding piece. The cannula exits from the device body in longitudinal direction and has lumen part passing through it that gives place to eye implant therein. The pusher is introducible into cannula lumen and movable from position one to position two. The binding piece has movable end connected to the pusher and fixed end attached to the device body. The movable end of the binding piece is movable relative to the device body from the position one to the position two when applying force to the binding piece being perpendicular to the device body axis causing said movement to take place. The binding piece has segments having flexible articulation. The device has means for holding the implant in the cannula lumen preventing accidental exit from the cannula. To introduce the eye microimplant, external eye layer is pierced and the cannula is introduced in required area. The pusher is moved from proximal cannula end towards the distal end, pushing the microimplant out.
 Medical product for calf diarrhea treatment / 2342122
Medical product contains polyvinylpyrolidone, Furacilinum, glucose, Acidum ascorbinicum and sodium hypochlorite at the certain component proportion.
|
FIELD: medicine. SUBSTANCE: for prevention of postoperative osteomyelitis use composition consisting of antimicrobial substances, dissolved in high-molecular polyvinylpyrolidone with molecular mass of 1 million. The composition is administered using a syringe into the medullar channel and in the intermuscular spaces surrounding a bone, on a measure of sealing of soft tissues after operation. Invention allows to give antimicrobial activity to tissues surrounding wound for long time at the expense of slow biodegradation of polyvinylpyrolidone and long-term diffusion of antimicrobial substances from a composition in a tissue. EFFECT: long finding of antimicrobial substances in tissues, prevention of development of postoperative osteomyelitis. 3 tbl
The invention relates to medicine, namely antimicrobial chemotherapy. Osteomyelitis remains one of the most pressing problems of traumatology and orthopedics. Most often purulent complications observed during intraosseous the osteosynthesis (28,2%); when combined osteosynthesis with the use of several different designs in combination with bone grafting, the imposition of fixation devices (11,3%); osteosynthesis with patch on the wound plates and beams (10,0%); at the osteosynthesis screws (9.8%) and with external vneochagovogo osteosynthesis(8,4%) [1]. Analogues of the proposed method are: the use of systemic antibiotics [1] and local application of antibiotics on polymeric carriers, such as polymethylmethacrylate (PMMA) [2]. The use of these funds is not significantly reduced the above indicators number of complications in the postoperative period. The release of gentamicin PMMA beads is slow and not in full. Bovine collagen is absorbable, good media for gentamicin, the latest fully released into the tissue with initially high concentrations. The researchers note that the maximum concentration of gentamicin in bone and surrounding tissues can be achieved almost immediately and significantly pre is yseut minimum overwhelming concentration for most bacteria, causing orthopedic infections. Recently attracts attention using biodegradable polymeric carriers for antibiotics. The closest analogue (prototype) of the present invention is a method of prevention of postoperative osteomyelitis in terms of osteosynthesis with the local use of the antibiotic gentamicin to biodegradation polymer carrier - collagen sponge [3]. The disadvantage of the prototype is that the bacterial action of aminoglycosides depends on their concentration, the higher is achieved in the first hours after their introduction. This explains why fast decrease of the level of gentamicin may prevent the development of postoperative bone infections (according to the authors), during the first seven days. At the same time, the authors note that often the remaining infection becomes reproducibles within two to three weeks, raising questions about the need to develop such a method of prophylaxis of postoperative osteomyelitis, which would extend the effect of antimicrobial substances, and to provide antimicrobial activity of the tissues surrounding the wound. This was the subject of the invention. The proposed method in terms of a single application of antimicrobial substances dissolved in a professional who ekulama polyvinylpyrrolidone with a molecular weight of 1 million, it is essential to prolong the effect of antimicrobial substances to impart antimicrobial activity to the tissues surrounding the wound for 3 weeks due to biodegradation of the polymer during this period. This ultimately leads to good clinical effect, namely the absence of inflammation in the tissues and the absence of microbial contamination of the tissues surrounding the wound. The result of the invention is achieved due to the fact that high-molecular polyvinylpyrrolidone with antimicrobial substances is within 3 weeks in the wound (on the bone surface, intermuscular, megascale space under the skin). When this occurs, the diffusion of antimicrobial substances in the tissue surrounding the wound, which imparts antimicrobial activity, persisting for 3 weeks. Shown in the tables following. Table 1: antimicrobial activity of the tissues surrounding the wound, in experimental animals at 21 days after surgery. The method of diffusion in agar. Table 2: Microbial infection of the tissues surrounding the wound, in experimental animals in the dynamics. Table 3: Presence of inflammation in the tissues surrounding the wound in experimental animals. The method is as follows. Based on the high molecular weight polyvinylpyrrolidone with a molecular weight of 1 million composition is prepared with antimicro the different substances in the permitted doses [4]. Composition (fit) was introduced by syringe into the bone marrow canal and intermuscular space surrounding bone, as the suturing of soft tissues after surgery. Based on the high molecular weight polyvinylpyrrolidone prepared 1%solution of the antibiotic amikacin and 1%solution of chemotherapeutic dioksidina. Was reproduced in the model of experimental acute osteomyelitis [3]. In the experiment used the rabbits of the Chinchilla breed weighing 3.0 to 3.5 kg as the infective agent was applied daily culture of Staphylococcus aureus strain 209 P "Oxford". All manipulations were carried out under intravenous hypentelium anesthesia. Under aseptic conditions from a longitudinal incision was revealing the tibial diaphysis, cortical layer was powerleveling 2 holes with a diameter of 1.0 mm at a distance of 1.0 cm and was filled with 0.1 N NaOH (50 μl) to obtain superficial necrosis of the bone. After 1 min the holes were filled with 0.5 ml of staphylococcal inoculum density of 2-108CFU/ml, and then 0.1 ml of the polymer composition. Then the holes were set pieces spokes Kirchner length of 0.5 cm Composition consisting of antimicrobial substances dissolved in the high-molecular polyvinylpyrrolidone with a molecular weight of 1 million, was injected by syringe into the bone marrow canal and intermuscular space surrounding bone,as the suturing of soft tissues after surgery. The animals were sacrificed experiment on the 7th, 14th and 21st day after the operation. The results of the observations are given in tables 1, 2, 3. The figures in table 1 demonstrate that the antimicrobial activity of the tissues surrounding the wound, in the animals treated with the application of the proposed method. In animals without treatment was observed phenomena of acute osteomyelitis confirmed clinically, microbiologically and morphologically (table 2-3). In the animals treated with the use of the proposed method, a clinically and morphologically revealed no signs of osteomyelitis; the same was confirmed and microbiological parameters (microbial infection of the tissues surrounding the wound): on the 7th day compared with the control seeding of bone marrow and bone was three orders of magnitude less than in the control; on the 14th day, respectively, 3 and 2; and on the 21st day was absent. In the control of infection of muscle tissue was 105bone marrow - 103bones - 102CFU/g Thus, as can be seen from the above example, the inventive method for the prevention of postoperative osteomyelitis, in contrast to the way the prototype allows us to give antimicrobial activity surrounding the wound tissues within 3 weeks and to prevent the development of osteomyelitis.
LITERATURE. 1. Cancer A.V. Postoperative osteomyelitis: Chapter 14. Surgical infection of musculoskeletal system. Osteomyelitis // Surgical infections: a Guide / edited by I.A. Erohina, BYR Gelfand, S.A. Shlyapnikova. - SPb: Peter, 2003. - S-749. 2. Papirov S. Pyo-septic surgery. Sofia: "Medicine and physical education, 1974. - S. 483 3. Riegels-Nielsen P., Espersen F., Rosenkrantz Hömlich L., Frimodt-Moller N. Collagen with gentamicin for prophylaxis of postoperative infection. // Acta Orthop Scand 1995; 66 (1): 69-72. 4. ON THE MAIN PAGE. Drugs is by drugs in Russia: a Handbook. - M.: Attraversare, 2005 - 1536 S. Method of prevention of postoperative osteomyelitis with use of antimicrobial substances on the polymer carrier, wherein the composition consisting of antimicrobial substances dissolved in the high-molecular polyvinylpyrrolidone with a molecular weight of 1 million injected by syringe into the bone marrow canal and intermuscular space surrounding bone, as the suturing of soft tissues after surgery.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||